Your browser doesn't support javascript.
loading
Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis.
Martín-Lluesma, S; Svane, I M; Dafni, U; Vervita, K; Karlis, D; Dimopoulou, G; Tsourti, Z; Rohaan, M W; Haanen, J B A G; Coukos, G.
Affiliation
  • Martín-Lluesma S; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona; Departamento de Ciencias Médicas Básicas, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.
  • Svane IM; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark.
  • Dafni U; Faculty of Nursing, National and Kapodistrian University of Athens, Athens, Greece; Department of Oncology, CHUV, University of Lausanne, Lausanne, Switzerland. Electronic address: udafni@nurs.uoa.gr.
  • Vervita K; Scientific Research Consulting Hellas, Statistics Center, Athens.
  • Karlis D; Department of Statistics, Athens University of Economics and Business, Athens, Greece.
  • Dimopoulou G; Scientific Research Consulting Hellas, Statistics Center, Athens.
  • Tsourti Z; Scientific Research Consulting Hellas, Statistics Center, Athens.
  • Rohaan MW; Division of Medical Oncology, Netherlands Cancer Institute (NKI), Amsterdam.
  • Haanen JBAG; Division of Medical Oncology, Netherlands Cancer Institute (NKI), Amsterdam; Department of Medical Oncology, Leiden University Medical Oncology, Leiden, Netherlands; Melanoma Clinic, CHUV, Lausanne.
  • Coukos G; Department of Oncology, Lausanne University Hospital and University of Lausanne Ludwig Institute for Cancer Research Lausanne Branch, Switzerland.
Ann Oncol ; 35(10): 860-872, 2024 Oct.
Article in En | MEDLINE | ID: mdl-39053767
ABSTRACT

BACKGROUND:

Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL-ACT) has consistently shown efficacy in advanced melanoma. New results in the field provide now the opportunity to assess overall survival (OS) after TIL-ACT and to examine the effect of prior anti-programmed cell death protein 1/programmed death-ligand 1 [anti-PD-(L)1] therapy on its efficacy.

METHODS:

A comprehensive search was conducted in PubMed up to 29 February 2024. Ιn this meta-analysis we focused on studies including high-dose interleukin 2, doubling the patient numbers from our previous meta-analysis conducted up to December 2018 and using OS as the primary endpoint. Objective response rate (ORR), complete response rate (CRR), and duration of response were secondary endpoints. Findings are synthesized using tables, Kaplan-Meier plots, and forest plots. Pooled estimates for ORR and CRR were derived from fixed or random effects models.

RESULTS:

A total of 13 high-dose interleukin 2 studies were included in this updated meta-analysis, with OS information available for 617 patients. No difference was found in median OS between studies with prior anti-PD-(L)1 treatment {n = 238; 17.5 months [95% confidence interval (CI) 13.8-20.5 months]} and without [n = 379; 16.3 months (95% CI 14.2-20.6 months)] (log-rank P = 0.53). ORR was estimated to be 34% (95% CI 16%-52%) and 44% (95% CI 37%-51%), for the studies with and without prior anti-PD-(L)1, respectively. The pooled estimate for CRR was 10% for both groups. No statistically significant difference was observed between the two groups, either for ORR (P = 0.15) or CRR (P = 0.45).

CONCLUSIONS:

Prior anti-PD-(L)1 treatment has no effect on the clinical response or survival benefit from TIL-ACT in advanced cutaneous melanoma. The benefit of TIL therapy in the second-line setting is also present after anti-PD-(L)1 treatment. Our data reinforce the evidence that TIL-ACT should be considered as a treatment of choice in second line for metastatic melanoma patients failing anti-PD-(L)1 therapy.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Lymphocytes, Tumor-Infiltrating / Melanoma Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2024 Type: Article Affiliation country: Spain

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Lymphocytes, Tumor-Infiltrating / Melanoma Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2024 Type: Article Affiliation country: Spain